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Abstract
Background: Current prevalence and genotype distribution of hepatitis C virus (HCV) infection remain unknown in
Ningxia, northwest China.
Methods: From June to December 2013, 13,022 individuals were screened in Ningxia HIV/AIDS Sentinel Surveillance
System, with their demographic features collected and serum samples tested for HCV antibody. Sero-positive drug
users were further subjected to sequencing of NS5B and Core regions of HCV.
Results: The anti-HCV prevalence was 0.34 % among individuals without history of drug use, while it was 15.80 %
among drug users. Of 79 NS5B sequences amplified from drug users, 64 (81.0 %) were male and 51 (64.0 %) were
injection drug users (IDUs). Subtype 3a (40.5 %) and 1b (25.3 %) were the most predominant subtypes, followed in
frequency by 3b (10.1 %) and 2a (7.6 %). Subtype distribution has no significant difference between injection and
non-injection drug users. Based on phylogeographic analysis, HCV strains in Ningxia IDUs were mainly originated from
two sites, Yunnan province (in southwest China bordering Myanmar, also known as Burma) and Xinjiang Autonomous
Region (in northwest China on the border of Central Asia), which are the two major drug trafficking originates in China.
Previously reported drug-resistance mutations were also scanned in this treatment-naïve population. Amino acid
substitutions (C316N) associated with direct anti-viral agents (DAA) resistance were identified in the NS5B region in
seven samples.
Conclusion: This study is the first to reveal the existence of multiple genotypes of HCV in Ningxia, an inland province
in northwest China, suggesting the rapid spreading of the virus.
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Background
Hepatitis C is the second leading cause of chronic hepa-
titis, liver cirrhosis and hepatocellular carcinoma (HCC)
in China. The seroprevalence of hepatitis C infection in
China is about 0.43 % in general population, correspond-
ing to 5.6 million people [1]. However, it has been
estimated that the real seroprevalence of HCV may be
close to 10 million in China [2]. In recent years,
although the overall hepatitis C virus (HCV) prevalence
is decreasing due to mandatory HCV antibody screening
prior to blood transfusion [3–5], the prevalence among
populations with high-risk behaviors remain high, espe-
cially among injection drug users (IDUs) [6, 7]. Studies
have shown that the prevalence of hepatitis C among
IDUs is 70 % in China [6, 8], compared to that of 60 %
in the United States [9].
HCV, a member of the family Flaviviridae, is a positive
single-stranded RNA virus. HCV is mainly divided into 7
genotypes and more than 80 subtypes. HCV genotype 1,
2, and 3 are commonly distributed around the world
[10]. Several nationwide studies have shown that geno-
type 1, 2, 3, 6 were the most prevalent genotypes in
China [11, 12]. The current genetic diversity of HCV
infection remains unclear in Ningxia Hui Autonomous
* Correspondence: hth09@mails.tsinghua.edu.cn
†Equal contributors
2Tsinghua University School of Medicine, Beijing 100084, China
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Wu et al. Virology Journal  (2016) 13:172 
DOI 10.1186/s12985-016-0635-y
Region, which is known for its ethnic diversity with
about 64.58 % Han, 35.42 % Hui (Muslims) and less than
1 % other minorities (Fig. 1) [13]. Han is the dominant
ethnic group in China with 90 % of the population, while
most of the Hui ethnic minority inhabit in Ningxia, is
descended from the Arabic and Persian merchants who
came to China during the 7th century [14].
As HIV and HCV share the same routes of transmission,
we recruited patients from Ningxia HIV/AIDS Sentinel
Surveillance System, part of the nationwide disease man-
agement program in China launched in 1995 [15, 16]. The
HIV/AIDS Sentinel Surveillance System is under the dir-
ection of the Ministry of Health (MOH) and the Chinese
Center of Disease Control and Prevention (CDC), with
nine key affecting populations (KAPs) were screened for
HIV infections and related behaviors (Additional file 1:
Supplementary Information 1). HCV testing was added
and routinely performed since 2009 [17]. Blood samples,
collected from KAPs registered from June to December
2013, were subjected to HCV tests, gene sequencing of
NS5B, Core regions and further analysis.
HCV genotyping and phylogenetic analysis provide
opportunity to reveal the recent HCV epidemic in
Ningxia and the possible transmission networks in
China. Such epidemiological and molecular informa-
tion can also inform the efficacy of current regimens
with Peginterferion and Ribavirin, and the upcoming
highly effective direct anti-viral agents (DAAs) as
well. Besides, few drug-resistance mutations have been
reported in China, where no DAAs have not been ap-
proved yet. Therefore, pre-treatment testing for indi-
viduals may benefit in regimen choosing more
effective regimens in the new DAA era.
Methods
Samples
Serum samples were collected from Ningxia HIV/AIDS
Sentinel Surveillance System, where nine groups of key
affecting populations (KAPs) were tested for HCV rou-
tinely, including 1) drug users (IDU and non-injection
drug users), 2) blood donors, 3) female sex workers
(FSW), 4) men who have sex with men (MSM), 5) sexual
Fig. 1 The map showing sampling spots in Ningxia and 17 provinces or municipalities in China, from which HCV reference sequences were
included in the phylogenetic analysis. The 17 provinces and municipalities were divided into five regions and colored accordingly: the northwest
(Xinjiang, Qinghai, Shaanxi), north & northeast (Liaoning, Beijing, Shanxi), southeast (Shanghai, Zhejiang, Jiangxi, Fujian), central south (Hubei,
Hunan, Guangdong, Hainan), and southwest (Sichuan, Yunnan, Guangxi). Ningxia is located in northwest China, with six cities Shizuishan (SZS),
Yinchuan (YC), Wuzhong (WZ), Zhongwei (ZW), Tongxin (TX), and Guyuan (GY) scattered from north to south where participants were recruited.
Major drug trafficking routes were shown by grey arrows referring to Sullivan et al. 2007, which originated from Yunnan (bordering Myanmar and
Laos) and Xinjiang (bordering Afghanistan and Pakistan), respectively [39]
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transmitted disease (STD) outpatients, 6) long-distance
truck drivers, 7) migratory populations, 8) pregnant
women and new mothers, and 9) young students, for
HIV, HCV and syphilis screening (Additional file 1:
Supplementary Information 1). In this study, only
HCV-antibody positive individuals were further
informed for detailed characteristics including age,
ethnics, occupation, education and drug use history,
using custom questionnaires.
HCV antibody and RNA testing, and RNA sequencing
HCV antibody testing was conducted using enzyme-
linked immunosorbant assay (ELISA) with HCV-IgG
ELISA kit (Wantai, Beijing, China), and positive results
were repeated twice for accuracy. HCV RNA was quan-
tified by real-time PCR, using Roche light cycle 2.0 Diag-
nostic Kit for hepatitis C virus RNA (PCR-Fluorescence
Probing) (Da’an, Shenzhen, China). HCV RNA positive
was defined as RNA copies over 0.5 × 103 IU/ml.
Samples with enough leftovers were further sent for
nested PCR and sequencing. Nested PCR was performed
as follows: the first round RT-PCR was performed using
One-Step RT-PCR kit (TransGene Biotech, Beijing,
China) using NS5B and Core specific external primers
with the following protocol: 45 °C 30 min, 94 °C 2 min,
(94 °C 30s, 50 °C 30s, 72 °C 90s) × 35 cycles, and 72 °C
10 min; the second round PCR was performed using
Promega Taq PCR Mastermix kit (Promega Company,
USA), using 5ul product from the first round as the
template, and NS5B and Core specific internal primers
(Additional file 1: Supplementary Information 3 and
Table S2), with the following protocol: (94 °C 2 min,
58 °C 30s, 72 °C 90s) × 30 cycles, and 72 °C 10 min.
The final PCR product was tested in agar gel electro-
phoresis and sent for Sanger sequencing.
HCV genotyping and mutation analysis
Four hundred fifteen NS5B reference sequences of sub-
type 1a, 1b, 2a, 2b, 3a, 3b, 6a, 6b, 6n, 6u, 6v were down-
loaded from GenBank, of which accession numbers were
KF585503 - KF585907, GQ206087, EU256071, AB661379,
JQ745651, KC844048, EU408332, EU408331, EU408330,
D84262, D37855. We performed sequence comparison
using the software MEGA 6.0, with the method of Clustal
W1.8, and constructed phylogenetic trees using
maximum-likelihood (ML) method and GTR+I+Γ model
[17–19]. The robustness of reconstructed phylogenies was
evaluated by bootstrapping (500 bootstrap replications) to
determine genotypes and calculate genetic distances be-
tween sequences. The tree topology based on NS5B and
Core regions were displayed as a circular form combined
with a pie chart of genotype distribution (Fig. 2a,
Additional file 1: Figure S1). Of all NS5B sequence
alignments, we scanned for previously published DAA-
resistant mutations on NS5B.
Phylogeographic analysis
Bayesian coalescent analysis was performed in BEAST
software (v1.8.3). The GTR+I+gamma substitution
model, uncorrected exponential clock model and
Bayesian skygrid coalescent model were selected [20],
and 5.0*10−4 substitution/site*year was set as the prior
rate [21]. The XML file was generated by BEUTi pro-
gram and ran in BEAST software, with MCMC run for
300,000,000 states and sampled every 10,000 states. The
consensus tree was generated in TreeAnnotator program
and Tracer program (v1.6.0), and deciphered in FigTree
program (v1.4.2).
Statistical analysis
We used R 3.0.2 for statistical analysis [22]. HCV sub-
type distribution was analyzed by Fisher’s exact test, and
p-value less than 0.05 were considered as statistically sig-
nificant. Kappa values were calculated to estimate the
agreement of NS5B and Core genotyping methods
(Additional file 1: Supplementary Information 2, and
Table S1) [23, 24].
Results
Epidemiology
Among 13,022 individuals recruited from Ningxia HIV/
AIDS Sentinel Surveillance System screened for anti-
HCV antibody, 2443 were drug users. The overall sero-
prevalence was 0.34 % among people with no history of
drug use, but as high as 5.8 % among drug users. 158
anti-HCV positive specimens were further tested for
HCV RNA with 132 being RNA positive. The estimated
HCV-RNA positive prevalence was 13.7 % for drug users
(Table 1). The prevalence of HCV was significantly
higher in IDUs, compared to non-injection drug users.
Demographic features
Among 79 drug users with a complete set of lab tests
and genotype determined, 81.0 % of currently HCV-
infected patients were male, 49.4 % were young adults
(younger than 40 years old), 87.3 % had middle school
or less education, and 69.6 % were unemployed. All drug
users have a history of drug use longer than one year,
and 64.6 % of them were IDUs. Nine patients (11.4 %),
all IDUs, were also HIV co-infected. Detailed demo-
graphic characteristics and drug use information were
summarized in Table 2.
Genotyping determination
Seventy-nine of those 116 RNA positive drug users were
sent for sequencing for NS5B region of HCV, and nine
subtypes were identified in total. Subtype 3a was the
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most common one, accounting for 40.5 % patients
(Fig. 2), followed by subtype 1b, 3b, and 2a, which took
25.3, 10.1 and 7.6 %, respectively. Several rare subtypes
were also identified, including five isolates identified as
subtype 6a, four isolates as subtype 6b, two isolates as
subtype 2b, one isolate as subtype 1a, and one isolate as
subtype 6u. Compared to subtype 1b, 3a was more often
found to be the younger and less often found among the
married (Fisher’s exact test, p < 0.05), which indicates an
emerging prevalence of subtype 3a infection among the
high-risk population in Ningxia. In addition, subtype 1a,
2b, 6u and 6b were exclusively found in IDUs. Genotyping
results based on Core region were present in Additional
file 1: Supplementary Information 2 and Figure S1.
Phylogenetic analysis
Bayesian phylogenetic trees by subtypes were recon-
structed for NS5B sequences to explore the possible
transmission patterns of HCV infections, based on a
large number of references from 17 provinces or munici-
palities and a few references of subtype 6u, 6b, 1a, and
2b strains from other provinces or countries outside
Fig. 2 Subtype distribution of HCV based on the NS5B sequences from 79 subjects. a The circular phylogenetic tree was generated using the
software MEGA 6.0, with maximum-likelihood (ML) method and GTR + I + Γ model with 500 bootstrap replications. HCV sequences were named
by “city of serum collection” and “ID number”, where YC, SZS, TX, GY, ZW, and WZ standing for six cities in Ningxia, that is, Yinchuan, Shizuishan,
Tongxin, Guyuan, Zhongwei, and Wuzhong, respectively. A pie chart showing the subtype distribution was combined with the tree topology.
b A bar chart showing the subtype distribution by cities in Ningxia
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China [19] (Fig. 1). For a better display, the Bayesian
phylogenetic tree was split into five subtrees represent-
ing different subtypes (Figs. 3 and 4).
Subtype 1b used to be the most prevalent subtype in
China, and strains from different regions were crossly dis-
tributed, suggesting simultaneous dissemination. In Fig. 3a,
four groups, namely Group A to D, have been designated
in previous studies with different geographic distributions
features [19]. Most sequences from Ningxia, however,
formed a cluster separately from Group A to D, indicating
the local spreading of HCV.
Two major groups of 2a were reported: Group A con-
tained sequences mainly from the northwest China, and
Group B from various regions in China [19] (Fig. 3b). Five
isolates, all collected from one rehabilitation center in
Yinchuan, Ningxia, formed a cluster with the posterior
probability of 0.99 in Group A. This cluster might descend
from a common ancestor in northwest China dated back
to year 1990s. In addition, two closely related isolates from
Shizuishan, Ningxia were identified as subtype 2b. As sub-
type 2b was rarely reported in China, such isolates might
imply possible real-world transmission pairs.
Subtype 3a sequences formed three separated geo-
graphic groups (Fig. 3c). Group A contained the majority
of 3a isolates in Ningxia and reference sequences from
central south China. Group B mainly contained sequences
form southwest China. The rest isolates formed Group C,
including sequences from neighboring Xinjiang province,
in northwest China, which was in consistency to the
known epidemic in the local area. Therefore, we hypothe-
sized that subtype 3a was introduced into Ningxia in
1990s simultaneously from three regions mentioned
above. Subtype 3b, unlike 3a, showed substantial mixture
of originates, and sequences in Ningxia also contributed
to the geographic interspersion (Fig. 3d).
The phylogeny of genotype 6 was reconstructed on the
basis of nine Ningxia sequences and 55 reference
sequences (Fig. 4). Three groups were noted among sub-
type 6a. We found that isolates of Ningxia were geo-
graphically interspersed among central south provinces
in China. Therefore, the possible migration trend might
arise from central south, spread to southeast and south-
west, and then transmit to the northwest China sporad-
ically. In addition, one close set of Ningxia sequences of
subtype 6a was found with full posterior probability of
1.00 in Group B, implying a possible transmission net-
work behind. Meanwhile, four Ningxia isolates clustered
together were closely related to two 6b strains, D84262
and D37855, reported in Thailand [25].
The homology of every cluster of subtype was as fol-
lows: 1b 95.14 %, 2a 96.91 %, 2b 92.90 %, 3a 95.69 %, 3b
96.72 %, 6a 98.27 %, 6b 98.30 %. Highest homology was
associated with subtype 6a and 6b, which suggested the
late introduction of these subtypes to Ningxia; and the
lowest homology (89.68 %) was associated with subtype
2b, indicating its long endemic history [26].
Mutation analysis
We scanned for previously reported DAA-resistant mu-
tations on NS5B, including S282T and C316N/Y in 79
NS5B sequences [27, 28]. No S282T samples were found,
and seven C316N resistance samples were found in 1b
subtype sequences, suggesting the natural occurrence of
Table 1 HCV seroprevalence and RNA positive prevalence of the screened population by risk behaviors
Population by risk factors Samples tested
antibody
Samples antibody
positive
Sero-prevalence Samples tested
RNA
HCV RNA+ Prevalence of HCV
RNA+
Sequenced for
NS5B region
Total 13,022 422 3.24 % 158 132 2.71 % 86
Drug users 2443 386 15.80 % 134 116 13.68 % 79
Injection drug user 601 284 47.25 % 82 73 42.07 % 51
Non-injection drug user 1842 102 5.54 % 52 43 4.58 % 28
Not Drug users 10,579 36 0.34 % 24 16 0.23 % 7
Blood donors 2099 3 0.14 % 0 0 - 0
Sex workers 2737 17 0.62 % 17 11 0.40 % 5
MSMs 400 0 0.00 % 0 0 - 0
Patients in STD clinics 2031 7 0.34 % 7 5 0.25 % 2
Long-distance truck drivers 100 2 2.00 % 0 0 - 0
Immigrants 400 1 0.25 % 0 0 - 0
Pregnant women 2012 2 0.10 % 0 0 - 0
College students 800 4 0.50 % 0 0 - 0
Nine groups from high- to low-risk populations were screened in Ningxia HIV/AIDS Sentinel Surveillance System, including 1) drug users (injection drug users and
non-injection drug users), 2) blood donors, 3) female sex workers (FSW), 4) men who have sex with men (MSM), 5) sexual transmitted disease (STD) outpatients, 6)
long-distance truck drivers, 7) migratory populations, 8) pregnant women, and 9) young students. The detailed criteria of the population were in Supplementary
information 1. Prevalence of HCV antibody (seroprevalence) and HCV RNA was higher among injection drug users than that among non-injection drug users
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DAA-resistant mutations in this treatment-naïve
population.
Discussion
We found that seroprevalence of HCV was 0.34 %
among individuals without drug use history and 15.8 %
for drug users in Ningxia, based on a screening on
individuals from Ningxia HIV/AIDS Sentinel Surveil-
lance System. Ningxia was conventionally considered as
a low-risk area, with the seroprevalence about 0.10 %
among general population [1, 29]. Specialists and clini-
cians suggested a higher prevalence since some high-risk
populations were not covered in the previous nationwide
survey. Therefore, we mainly focused on drug users
Table 2 Genotype distribution of 79 drug users by demographic features
Genotype All 1a 1b 2a 2b 3a 3b 6a 6b 6u p-valuea
Overall 79 1 20 6 2 32 8 5 4 1
Sex 0.589
Male 64 1 17 6 1 24 6 5 3 1
Female 15 0 3 0 1 8 2 0 1 0
Age 0.013
<30 14 1 4 2 0 5 1 1 0 0 0.843
31–40 25 0 1 1 0 15 3 2 3 0 0.010
41–50 36 0 15 2 2 11 3 1 1 1 0.029
≥50 4 0 0 1 0 1 1 1 0 0 0.117
Marriage 0.003
Unmarried 32 0 5 2 1 19 2 2 1 0 0.111
Married 16 1 3 4 0 3 4 0 1 0 0.004
Divorced or Widow 31 0 12 0 1 10 2 3 2 1 0.035
Ethnics 0.163
Han 40 0 12 2 1 18 1 3 2 1 0.153
Hui 31 0 5 3 1 11 7 2 2 0 0.033
Others 8 1 3 1 0 3 0 0 0 0 0.721
Education 0.175
Elementary school 35 1 10 5 0 9 3 4 3 0 0.035
Middle school 34 0 7 1 2 19 3 1 0 1 0.158
High school or college 10 0 3 0 0 4 2 0 1 0 0.754
Occupation 0.178
Employed 24 0 6 3 0 7 5 1 1 1
Unemployed 55 1 14 3 2 25 3 4 3 0
Drug use method 0.402
Injection drug user 51 1 13 4 2 19 6 1 4 1
Non-injection drug user 28 0 7 2 0 13 2 4 0 0
Drug use duration 0.069
<1 year 0 0 0 0 0 0 0 0 0 0 1.000
1–2 years 12 0 4 0 0 6 2 0 0 0 0.735
3–4 years 25 0 5 2 0 7 4 4 3 0 0.072
5–10 years 23 1 3 4 0 12 2 0 0 1 0.060
>10 years 19 0 8 0 2 7 0 1 1 0 0.117
HIV co-infection 0.061
Yes 9 1 2 2 0 1 2 0 0 1
No 70 0 18 4 2 31 6 5 4 0
HCV subtypes were determined by the sequence NS5B
aRare subtypes including 1a, 2b, 6b, and 6u were removed from Fisher’s exact test. p < 0.05 were bolded
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recruited from HIV surveillance system. We found that
the prevalence among drug users was comparable to that
of neighboring provinces but lower than the reported
prevalence nationwide, that was, 66.97 % for IDUs and
18.97 % for non-injection drug users [8, 30].
Previous genotyping studies provided evidences to the
hypothesis of two epidemics of HCV in China. Blood trans-
fusion contributed to the first epidemic in China [31].
Subtype 1b, followed by 2a, was reported to be the most
predominant subtypes in those studies that screened more
blood donors [19, 32, 33]. Mandatory screening of blood
and blood products was implemented in the 1990s to pre-
vent the spreading of HCV [5]. Together with the increasing
number of drug users, several studies have noticed a shift to
the second epidemic: from subtype 1b to genotype 3 and 6
[34–37]. In addition, IDU is suspected as a factor that drives
the emerging of new subtypes mainly due to genetic drift
[38]. In our study, nine subtypes were identified, in which 3a
Fig. 3 Bayesian phylogenetic tree based on NS5B from sequences from this study (labeled in red) along with 415 reference strains of 1b, 2a, 3a,
and 3b. The geographic location of those sequences was mapped in Fig. 2. a The Bayesian tree of subtype 1b. b The Bayesian tree of subtype 2a.
c The Bayesian tree of subtype 3a. d The Bayesian tree of subtype 3b
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(41.38 %) and 1b (25.29 %) were the predominant subtypes.
Subtype 1a, 2b, 6u and 6b were not reported in Lu et al.
[19], which was the largest genotyping study in China so far.
The finding of multiple genotypes in Ningxia including fairly
rare subtypes reflected the substantial mixture of HCV pa-
tients and accelerated propagation of the disease by modern
transportation, internal migration, blood transfusion and
IDU.
Studies on drug trafficking routes suggested the correl-
ation of HIV transmission network and the drug smug-
gling routes from two major heroin-producing regions,
“The Golden Triangle” (Myanmar, Laos and Thailand)
and “The Golden Crescent” (Afghanistan and Pakistan)
[39]. HCV shared the same way of transmission and thus
the same epidemic features with HIV. The geographic fea-
tures of HCV prevalence reinforced its spreading through
these two drug trafficking routes [8]. Ningxia is located at
the crossroad of the two drug trafficking routes geograph-
ically (Fig. 1). Phylogenetic analysis of subtype 3a also
suggested the virus in Ningxia comes from both origi-
nates, Yunnan (bordering Myanmar and Laos) and
Xinjiang (bordering Afghanistan and Pakistan) (Fig. 3c).
We found 11 co-infected patients of both HIV and
HCV (13.9 %), which is much higher than the prevalence
of 1.88 % among drug users in prior studies [8, 40]. This
inconsistency may be due to the sampling bias, as samples
collected in this study are from HIV/AIDS Sentinel
Surveillance System. Besides, very few studies have been
performed on mixed infection of different subtypes of
HCV, which may be a hint for viral reconstruction, and a
boost to fasten viral evolution [34]. Conventional sequen-
cing methods based on short regions would not enable us
to confirm hybrid genetics even if it exists. Further studies
need to be performed on the detection of the intra-host
viral population with deep sequencing [41].
With regard to the naturally occurring drug-resistance
mutations, several single nucleotide polymorphisms
(SNPs) of NS5B protease resistance have been previously
reported in treatment-naïve hepatitis C patients [28, 42].
As the first DAA will be introduced to China soon,
searching for drug-resistance SNPs may impact the plan-
ning for HCV treatment and predict the disease burden
in the future. S282T was the most common one con-
ferred resistance to NS5 nucleoside analogs inhibitors,
such as Sofosbuvir, in subtype 1a, 1b and modest resist-
ance in subtype 2a [43, 44]. In this study, we found no
such resistance-bearing viral strains. However, C316N
were detected in seven isolates among 1b sequences,
which was reported to be associated with resistance to
non-nucleotide inhibitor of NS5 protease [45–47]. Seven
C316N-bearing sequences form two fairly close-related
clusters, implying a direct transmission network behind,
which calls for behavior study to confirm.
The findings of this study may impact the HCV control-
ling approaches in terms of screening, treatment, and pa-
tients management. First, several studies have suggested
that interventions targeting drug users were effective ap-
proaches for HCV control [48, 49]. Continued screening,
monitoring and treatment for drug users may reduce
HCV incidence and prevalence, and could be highly cost-
effectiveness. Second, needle exchange programs (NEP)
and methadone maintenance treatment (MMT) may also
be a feasible approach in controlling HCV transmission
among IDUs. There are currently eight NEP/MMT sites
operating in Ningxia, but still 23.1 to 44.4 % IDUs re-
ported sharing needles in a recent survey conducted in
2015 [50, 51]. Our findings highlighted the necessity of
the expansion of NEP in Ningxia and increased financial
investment to such programs. In addition, treatment with
the implementation of new DAAs could be highly effect-
ive, whereas their cost and value had been widely debated
as the DAA treatment is much too expensive. Besides, the
complex treatment regimen for HCV is further compli-
cated by HIV co-infection [52, 53].
This study has several limitations. First, all serum sam-
ples were collected from individuals presented in HIV/
AIDS Sentinel Surveillance System in 2013, and therefore
the prevalence could not reflect that of general population.
Fig. 4 Bayesian phylogenetic tree based on NS5B from nine sequences (labeled in red) along with 55 references of 6a and 6b
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Further studies on the phylogeny on sequences from gen-
eral population may present with a different pattern. Sec-
ond, only NS5B and Core sequences were analyzed in our
study. Whole genome sequencing performed on deep se-
quencing would provide more information on genotype
distribution and mixed infection of various strains within
one host [41]. Third, we did not collect enough clinical
data, such as liver biopsy, aminotransferase/platelet ratio
index (APRI) or FIB-4 scores, and thus were not able to
stratify our patients by their liver status [54–56].
Conclusion
In conclusion, the overall seroprevalence of HCV was
0.34 % among people with no history of drug use in
Ningxia, while it was 15.8 % among drug users and
47.25 % among IDUs, based on a screening on individuals
from Ningxia HIV/AIDS Sentinel Surveillance System.
Nine subtypes, 1a, 1b, 2a, 2b, 3a, 3b, 6a, 6b and 6u were
found among 79 isolates from drug users. 3a (41.38 %)
followed by 1b (25.29 %) were the most predominant.
Phylogenetic analysis suggested two possible originates of
HCV transmission, accompanying the drug trafficking
route in China. Our study suggested that drug use, espe-
cial IDU, is the most important risk factor for HCV infec-
tion, and management of drug users in Ningxia may play
a crucial role in controlling the ongoing HCV epidemic.
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